CN114375305A - Cr2结合蛋白及其在医学疗法中的用途 - Google Patents

Cr2结合蛋白及其在医学疗法中的用途 Download PDF

Info

Publication number
CN114375305A
CN114375305A CN202080060956.4A CN202080060956A CN114375305A CN 114375305 A CN114375305 A CN 114375305A CN 202080060956 A CN202080060956 A CN 202080060956A CN 114375305 A CN114375305 A CN 114375305A
Authority
CN
China
Prior art keywords
binding protein
seq
amino acid
acid sequence
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080060956.4A
Other languages
English (en)
Chinese (zh)
Inventor
J.M.贝利
G.布马
M.N.伯登
C.J.迪梅奇
D.迪克森
G.多斯桑托斯克鲁兹德曼托斯
C.埃尔森
L.J.胡克
S.基钦
E.莱科瓦
E.马杜拉
K.尼斯塔拉
J.张
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of CN114375305A publication Critical patent/CN114375305A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080060956.4A 2019-08-30 2020-08-28 Cr2结合蛋白及其在医学疗法中的用途 Pending CN114375305A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1912437.9 2019-08-30
GBGB1912437.9A GB201912437D0 (en) 2019-08-30 2019-08-30 CR2 Binding Proteins and their use in Medical Therapy
PCT/EP2020/074049 WO2021038023A1 (en) 2019-08-30 2020-08-28 Cr2 binding proteins and their use in medical therapy

Publications (1)

Publication Number Publication Date
CN114375305A true CN114375305A (zh) 2022-04-19

Family

ID=68207176

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080060956.4A Pending CN114375305A (zh) 2019-08-30 2020-08-28 Cr2结合蛋白及其在医学疗法中的用途

Country Status (14)

Country Link
US (1) US20230032643A1 (enExample)
EP (1) EP4021938A1 (enExample)
JP (1) JP7603061B2 (enExample)
KR (1) KR20220053000A (enExample)
CN (1) CN114375305A (enExample)
AR (1) AR119865A1 (enExample)
AU (1) AU2020338807A1 (enExample)
BR (1) BR112022003623A2 (enExample)
CA (1) CA3151687A1 (enExample)
GB (1) GB201912437D0 (enExample)
IL (1) IL290649A (enExample)
MX (1) MX2022002478A (enExample)
TW (1) TWI851801B (enExample)
WO (1) WO2021038023A1 (enExample)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291239B1 (en) * 1998-09-25 2001-09-18 Wolfgang Prodinger Monoclonal antibody
CN1756560A (zh) * 2002-11-15 2006-04-05 Musc研究发展基金会 通过补体受体2定向的补体调节剂
US20130190477A1 (en) * 2010-05-14 2013-07-25 The Regents Of The University Of Colorado Complement receptor 2 (cr2) targeting groups
CN108137669A (zh) * 2015-05-18 2018-06-08 蓝鸟生物公司 抗ror1嵌合抗原受体
US20190144514A1 (en) * 2016-04-27 2019-05-16 The Regents Of The University Of Michigan C3d cellular and acellular vaccines for the prevention and treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
JP2004529945A (ja) * 2001-05-17 2004-09-30 ラ ホヤ ファーマシューティカル カンパニー Ｃｄ２１を阻害する薬剤を使用して抗体媒介性病理を処置する方法
US20050164301A1 (en) 2003-10-24 2005-07-28 Avidia Research Institute LDL receptor class A and EGF domain monomers and multimers
US8961967B2 (en) 2009-11-30 2015-02-24 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291239B1 (en) * 1998-09-25 2001-09-18 Wolfgang Prodinger Monoclonal antibody
CN1756560A (zh) * 2002-11-15 2006-04-05 Musc研究发展基金会 通过补体受体2定向的补体调节剂
US20130190477A1 (en) * 2010-05-14 2013-07-25 The Regents Of The University Of Colorado Complement receptor 2 (cr2) targeting groups
CN108137669A (zh) * 2015-05-18 2018-06-08 蓝鸟生物公司 抗ror1嵌合抗原受体
US20190144514A1 (en) * 2016-04-27 2019-05-16 The Regents Of The University Of Michigan C3d cellular and acellular vaccines for the prevention and treatment of cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
G. SZAKONYI等: "Structure of Complement Receptor 2 in Complex with Its C3d Ligand", SCIENCE, vol. 292, no. 5522, pages 1725 - 1728 *
GUTHRIDGE J M等: "Epitope mapping using the X-ray crystallographic structure of complement receptor type 2 (CR2)/CD21: identification of a highly inhibitory monoclonal antibody that directly recognizes the CR2-C3d interface", THE JOURNAL OF IMMUNOLOGY, vol. 167, no. 10, pages 5758 - 5766, XP002318006 *

Also Published As

Publication number Publication date
TW202126687A (zh) 2021-07-16
IL290649A (en) 2022-04-01
AU2020338807A1 (en) 2022-03-10
JP7603061B2 (ja) 2024-12-19
AU2020338807A8 (en) 2022-06-02
EP4021938A1 (en) 2022-07-06
JP2022545947A (ja) 2022-11-01
TWI851801B (zh) 2024-08-11
AR119865A1 (es) 2022-01-19
US20230032643A1 (en) 2023-02-02
GB201912437D0 (en) 2019-10-16
MX2022002478A (es) 2022-03-22
CA3151687A1 (en) 2021-03-04
KR20220053000A (ko) 2022-04-28
WO2021038023A1 (en) 2021-03-04
BR112022003623A2 (pt) 2022-05-24

Similar Documents

Publication Publication Date Title
JP7486636B2 (ja) 抗ｍｓ４ａ４ａ抗体及びその使用方法
US11472882B2 (en) Anti-B7-H4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
CN109069620B (zh) 拮抗剂ccr7受体的人源化抗体
KR20200054133A (ko) Ig 및 itim 도메인을 갖는 t 세포 면역 수용체 (tigit)에 대한 항체 및 이것의 사용
CN110392694A (zh) 针对pd-1的抗体及其用途
WO2021180205A1 (zh) Pvrig结合蛋白及其医药用途
CN114728065A (zh) 针对cd3和bcma的抗体和自其制备的双特异性结合蛋白
TWI874431B (zh) 抗ms4a4a抗體及其使用方法
CN115768793A (zh) 新型lilrb2抗体和其用途
JP2026050358A (ja) 治療用抗ｃｄ４０リガンド抗体
BRPI1014016B1 (pt) anticorpos humanizados para receptor tipo toll 2 e usos dos mesmos.
JP7843824B2 (ja) 抗体および使用方法
TWI873313B (zh) 一種免疫細胞啟動劑的開發及應用
EP4403573A1 (en) Pharmaceutical composition comprising anti-pvrig/tigit bispecific antibody
US12606619B2 (en) Human monoclonal antibodies against TIGIT for immune related diseases
WO2017122666A1 (ja) 抗Ｍｙｌ９抗体
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
JP7430137B2 (ja) 抗体および使用方法
CN114375305A (zh) Cr2结合蛋白及其在医学疗法中的用途
TWI833227B (zh) 靶向pd-l1和cd73的特異性結合蛋白及其應用
WO2022012639A1 (zh) Pd-1抗原结合蛋白及其应用
HK40067877A (en) Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom
HK1255020B (en) Humanized anti-ccr7 receptor antibodies
HK1255020A1 (en) Humanized anti-ccr7 receptor antibodies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20250530

AD01 Patent right deemed abandoned